Metformin Inhibits Gluconeogenesis by a Redox-Dependent Mechanism In Vivo

Metformin, the universal first-line treatment for type 2 diabetes, exerts its therapeutic glucose-lowering effects by inhibiting hepatic gluconeogenesis. However, the primary molecular mechanism of this biguanide remains unresolved, though it has been suggested to act, at least partially, by mitocho...

Descripción completa

Detalles Bibliográficos
Autores principales: Madiraju, Anila K., Qiu, Yang, Perry, Rachel J., Rahimi, Yasmeen, Zhang, Xian-Man, Zhang, Dongyan, Camporez, João-Paulo G., Cline, Gary W., Butrico, Gina M., Kemp, Bruce E., Casals, Gregori, Steinberg, Gregory R., Vatner, Daniel F., Petersen, Kitt Falk, Shulman, Gerald I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6129196/
https://www.ncbi.nlm.nih.gov/pubmed/30038219
http://dx.doi.org/10.1038/s41591-018-0125-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6129196/
https://www.ncbi.nlm.nih.gov/pubmed/30038219
http://dx.doi.org/10.1038/s41591-018-0125-4

Ejemplares similares